Grifols (BME:GRF) Stock Still Looks Cheap Based On Current Earnings

Grifols has seen sharp swings over recent years, and that kind of ride naturally raises a blunt question for you as an investor: Does the current share price line up with what the business is actually earning today?

• The stock has fallen 44.9% over the past 5 years, which puts the spotlight firmly on whether the current valuation still lines up with its underlying earnings power.

• For a plasma focused healthcare group that relies heavily on converting collection capacity and manufacturing efficiency into profit, any change in cost discipline or pricing power can reshape what its earnings stream is worth today.

• There is a second opinion on Grifols worth weighing. See what analysts think Grifols's shares could be worth .

The stock's next move may depend on whether Grifols' current earnings are strong enough to support the price investors are paying today.

If you want to test the same earnings question you are asking of Grifols against a broader set of ideas, take a look at 195 high quality undervalued stocks .

Is Grifols Still Cheap on Earnings?

P/E fits Grifols reasonably well because earnings still act as the main anchor for how investors appraise the business today. On this lens, the stock trades on a P/E of 16.1x, which is well below the broader biotech sector on 23.9x and also under the 23.4x peer group average. That gap indicates that the market is not paying the same headline price for each euro of Grifols' earnings as it is for many plasma and biotech rivals.

The fair P/E that aligns with Grifols' own profile is higher than where the shares trade, so the current 16.1x screens as undervalued on this framework. To decide how much weight to put on that discount, you would still want to consider factors such as balance sheet risk, the quality of plasma-derived earnings and how consistent cash generation looks across a cycle. If those fundamentals appear solid to you, the present P/E level may look more like a potential opportunity than a red flag for this particular stock. Explore the numbers behind Grifols's P/E valuation .

The Grifols Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Grifols try to answer the next obvious question after the P/E puzzle. They spell out what kind of path for Grifols' growth, profitability and earnings would need to hold for the share price to look meaningfully higher or lower than it does today. Each scenario ties its number back to a clear view of where revenue momentum, margin shape and key risks might head, so you can revisit that logic as fresh information comes through.